Metastatic Uveal Melanoma Epidemiology

Key Highlights

 

• The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Uveal Melanoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

• Uveal Melanoma is a rare condition accounting for only 5% of all primary melanoma cases. Still, it is the most frequently diagnosed primary intraocular malignant tumor in adults. Early diagnosis and local treatment is crucial, as survival correlates with primary tumor size. However, approximately 50% of patients will develop metastatic disease with 6–12 months’ survival from metastatic diagnosis.

 

• Metastatic Uveal Melanoma epidemiology is segmented as Total Incident Cases of Uveal Melanoma, Gender-specific cases of Uveal Melanoma, Age-specific cases of Uveal Melanoma, and Type-specific cases of Uveal Melanoma] in the Metastatic Uveal Melanoma epidemiology report.

 

Request for unlocking of Metastatic Uveal Melanoma Epidemiology

 

DelveInsight's ‘Metastatic Uveal Melanoma Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Uveal Melanoma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Geography Covered

• The United States
• EU4 (Germany, Spain, Italy, and France) and the United Kingdom
• Japan

 

Study Period: 2021-2034

 

Metastatic Uveal Melanoma Epidemiology Disease Understanding

The DelveInsight’s Metastatic Uveal Melanoma epidemiology report gives a thorough understanding of Metastatic Uveal Melanoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Uveal Melanoma (UM) is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid.  This malignancy arises from melanocytes in the choroid, ciliary body, or iris. The choroid posterior to the equator, hereafter referred to as the posterior choroid, is the most common site involved with approximately 85% of cases localized to this region.

 

The most common primary symptom in UM is blurred vision (37.8%), however, many patients are asymptomatic at the time of diagnosis (30.2%). Other common symptoms at presentation include photopsia (8.6%), floaters (7%), visual field loss (6.1%), visible tumor (3.1%), pain (2.4%), and metamorphopsia (2.2%).

 

Metastatic Uveal Melanoma Diagnosis

The diagnosis is based principally on clinical examination of the tumor with biomicroscopy and indirect ophthalmoscopy and confirmed by diagnostic techniques such as ultrasonography, fundus fluorescein angiography and optical coherence tomography. The clinical diagnosis of posterior uveal melanomas can be made when the classical appearance of a pigmented dome-shaped mass is detected on dilated fundus exam. Uveal melanomas classically show low to medium reflectivity on A-scan ultrasonography and on B-scan ultrasonography the tumor appears as a hyperechoic, acoustically hollow intraocular mass.

 

Metastatic Uveal Melanoma Epidemiology

The Metastatic Uveal Melanoma epidemiology section provides insights about historical and current Metastatic Uveal Melanoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Uveal Melanoma epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

• Uveal Melanoma is a rare condition accounting for only 5% of all primary melanoma cases. Still, it is the most frequently diagnosed primary intraocular malignant tumor in adults. Early diagnosis and local treatment is crucial, as survival correlates with primary tumor size. However, approximately 50% of patients will develop metastatic disease with 6–12 months’ survival from metastatic diagnosis.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Metastatic Uveal Melanoma epidemiology [segmented as Total Incident Cases of Uveal Melanoma, Gender-specific cases of Uveal Melanoma, Age-specific cases of Uveal Melanoma, and Type-specific cases of Uveal Melanoma] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

Country Wise- Metastatic Uveal Melanoma Epidemiology

This section provides a glimpse of the Metastatic Uveal Melanoma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

KOL- Views

To keep up with the current Metastatic Uveal Melanoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Metastatic Uveal Melanoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Metastatic Uveal Melanoma (MUM) Market
 

Scope of the Metastatic Uveal Melanoma Epidemiology Report

• The report covers the descriptive overview of Metastatic Uveal Melanoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States,EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Metastatic Uveal Melanoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Uveal Melanoma, Gender-specific cases of Uveal Melanoma, Age-specific cases of Uveal Melanoma, and Type-specific cases of Uveal Melanoma

 

Metastatic Uveal Melanoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Uveal Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metastatic Uveal Melanoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Metastatic Uveal Melanoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Metastatic Uveal Melanoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Metastatic Uveal Melanoma Epidemiology Segmentation

 

Metastatic Uveal Melanoma Report Assessment

• Disease Understanding
• Current Diagnosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Metastatic Uveal Melanoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Metastatic Uveal Melanoma patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Metastatic Uveal Melanoma in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Metastatic Uveal Melanoma?
• Out of all 7MM countries, which country would have the highest incident population of Metastatic Uveal Melanoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Metastatic Uveal Melanoma Disease market
• To understand the future market competition in the Metastatic Uveal Melanoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Uveal Melanoma Disease in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Metastatic Uveal Melanoma Disease market
• To understand the future market competition in the Metastatic Uveal Melanoma Disease market